Why VC Due Diligence Is Not Enough for Science Industrialization
Aktualisiert: 18. Sept.
Venture capital due diligence can be rigorous and still answer the wrong question for an industrial transition.
The issue is not that VC investors fail to investigate companies. It is that their diligence is designed for an ownership decision under a portfolio model.
An industrial customer, company board or public institution carries different consequences. It may need confidence that a technology can be integrated into a regulated process, delivered at consistent quality, governed through a supply chain and supported over a long asset life. A failure may interrupt a plant, create clinical liability or weaken strategic capability. It cannot always be diversified away.
What VC due diligence is designed to decide
A venture investor asks whether the team, technology, market, transaction terms and possible outcomes justify acquiring an ownership position in a highly uncertain company. The fund can tolerate many weak or failed investments if a small number of exceptional outcomes return the portfolio.
That makes uncertainty acceptable when expected upside, portfolio construction and deal terms compensate for it. The diligence may be fully appropriate for the investor while remaining insufficient for another actor who is considering adoption, procurement or infrastructure dependence.
The practical mistake begins when the investor’s approval is treated as universal proof of readiness.
Asset-selection diligence and transition diligence are different
Asset-selection diligence asks whether an investment can produce an attractive risk-adjusted return under a portfolio and ownership model.
Transition diligence asks whether the proposed company, capital and operating architecture can complete a particular technical, regulatory, industrial or commercial change.
The second does not replace financial, technical, legal, commercial or IP diligence. It connects their findings to the commitment actually under consideration. Its unit of analysis is not only the company, but the company in relation to the environment through which it must move.
For complex technologies, that environment may include regulators, industrial customers, laboratories, contract manufacturers, insurers, infrastructure owners, standards bodies, public procurement authorities and several types of capital provider.
The decisive question becomes: Is the available evidence sufficient for this actor to make this commitment under the consequences it must carry?
More diligence does not guarantee better decision fit
Debates about venture diligence often focus on depth. More investigation is assumed to be safer; less investigation is associated with competitive deals and market heat.
Depth matters, but fit matters more. Evidence gathered for an investment decision can be detailed and still fail to support an industrial or governance decision. The difference comes from responsibility.
Investors may accept technical uncertainty when upside and portfolio economics justify it.
Industrial customers need evidence about integration, continuity, service and failure consequences.
Public funders must consider additionality, capability and strategic outcomes beyond private return.
Boards must consider sequencing, obligations and the survival of the company as a whole.
None of these perspectives is inherently superior. Each protects a different decision.
The danger of borrowed assurance
Once a respected investor, agency or corporate partner participates, later actors assume that the important questions have already been checked. Institutional participation becomes a form of assurance.
This inference is understandable, but every review is bounded by mandate, cost and objective. An investor can accept a risk that a customer cannot. A corporate innovation team may confirm technical interest without committing the operating business. A public programme may establish eligibility and strategic relevance without testing the commercial route.
Borrowed assurance becomes dangerous when nobody can explain what earlier diligence was intended to prove—and what it deliberately left unresolved.
Why several specialist reports may still be incoherent
A transaction can include competent financial, technical, legal, commercial and IP reports and still lack an integrated judgement.
The market review may assume laboratory performance transfers into customer conditions. The financial model may assume production learning follows capital expenditure. The technical report may establish feasibility without addressing organisational adoption. The IP opinion may confirm ownership while leaving dependence on key people or partners untouched.
No report needs to be wrong. The failure occurs when nobody owns the meaning of the findings taken together.
Five consequences of using diligence for the wrong decision
False comfort: investor participation is mistaken for industrial validation.
Duplicated work without synthesis: specialists produce reports, but their assumptions are never tested against one another.
Evidence-cost mismatch: a proportionate investment review is reused for a public or industrial commitment with much larger failure consequences.
Conflicting objectives: an investor’s return logic is imported into a decision serving customers, infrastructure, workforce or regional capability.
Reputational contagion: the presence of credible institutions begins to carry more weight than independent evidence.
This is also why early financing can reduce a science venture’s strategic options. Capital does not only fund progress; it can select a pathway before the wider transition has been tested.
How to make deep tech diligence decision-specific
The answer is not another generic checklist or a longer risk catalogue. Leaders should first define the commitment: who is deciding, what becomes difficult to reverse, which consequences that actor carries and which dependencies must hold simultaneously.
Existing specialist work can then be tested for coverage, compatibility and missing decision evidence. The output should be a defensible judgement about whether the evidence can carry the proposed commitment—not an attempt to reward analytical volume.
I develop decision-specific transition reviews for public institutions, boards and industrial partners, complementing established legal, financial and technical diligence. Related work on the founder and company side is available through venture commercialisation pathways.
For the strategic constraints created by early financing, read The First VC Check Can Reduce a Science Venture’s Strategic Options.
The decision diligence must defend
VC due diligence selects and structures ownership under uncertainty. Industrial transition requires coordinated capability under consequence. A company can pass the first test and remain unready for the second.
That is not necessarily a failure of venture diligence. It is a failure to define whose decision the evidence was supposed to defend.
Kommentare